Meeting
2023 ASCO Breakthrough
Mechanism of action (MOA) for TGF-ß2 driven survival.
Authors
Vuong N. Trieu
Oncotelic Therapeutics, Agoura Hills, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 70)
DOI
10.1200/GO.2023.9.Supplement_1.70
Abstract #
70
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer.
First Author: Xianming Huang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.
First Author: Takafumi Okayama
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors